Published in

Ferrata Storti Foundation, Haematologica, 9(92), p. 1238-1241

DOI: 10.3324/haematol.11369

Links

Tools

Export citation

Search in Google Scholar

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

Journal article published in 2007 by Franck E. Nicolini, Sandrine Hayette, Selim Corm, Emmanuel Bachy ORCID, Dominique Bories, Michel Tulliez, François Guilhot, Laurence Legros, Frédéric Maloisel, Jean-Jacques Kiladjian, François-Xavier Mahon, Q.-H. Le, Quoc-Hung Lê, Mauricette Michallet, Catherine Roche-Lestienne and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

We analyzed 27 CML patients treated with imatinib (IM) who developed a BCR-ABLT315I mutation. These patients had poor prognostic features: High or intermediate Sokal index (82%), and lack of CCyR under IM (59%). At T315I discovery, patients were in advanced phase (59%), with clonal evolution (84%). Median time since diagnosis was 39 months, and progression occurred 13 months after IM initiation, regardless of disease phase. Overall survival since IM initiation was 42.5 months for chronic, and 17.5 months for advanced phases, and all patients progressed. This mutation seems related to or (partially?) responsible for progression and poor survival.